AriBio's AR1001, a Viagra-like Drug, Shows Promise in Slowing Alzheimer's Progression in Clinical Trials
AriBio, a South Korean pharmaceutical company, has announced promising results from a Phase 3 clinical trial for its drug AR1001, which is designed to slow the progression of Alzheimer's disease. The drug, a phosphodiesterase-5 inhibitor similar to Viagra, demonstrated a 31% reduction in cognitive decline over one year in patients with early Alzheimer's who were not receiving other treatments. The trial, which spanned 13 countries and included 604 participants in this specific subgroup, presented its findings at the Clinical Trials on Alzheimer's Disease conference in Boston. AR1001 works by relaxing blood vessels and increasing blood flow to the brain, and it also appears to directly stimulate pathways in brain cells that promote learning and memory. While the results are encouraging for patients not on other Alzheimer's medications, the drug did not achieve statistically significant results in a wider group of patients who were also taking other Alzheimer's drugs. AriBio plans to seek FDA approval for AR...